Abstract Number: 1419 • 2019 ACR/ARP Annual Meeting
Cost-per-Responder Analysis of Sarilumab for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (RA)
Background/Purpose: Network meta-analyses (NMA) have been conducted to compare the efficacy and safety of sarilumab, a fully human monoclonal antibody against the interleukin 6 receptor…Abstract Number: 1420 • 2019 ACR/ARP Annual Meeting
Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)
Background/Purpose: In many countries, JAK-inhibitors (JAKi) have been recently accepted for the treatment of patients with rheumatoid arthritis (RA). However, prescription patterns may differ notably…Abstract Number: 1421 • 2019 ACR/ARP Annual Meeting
Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results
Background/Purpose: In patients with Rheumatoid Arthritis (RA), qualitative alterations of low and high density lipoproteins (LDL and HDL, respectively) might partially explain their increased cardiovascular…Abstract Number: 1422 • 2019 ACR/ARP Annual Meeting
Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA
Background/Purpose: T-cell profiles are heterogeneous between individuals and consist of naïve T cells, memory T cells (including effector memory T cells [TEM] and central memory…Abstract Number: 1423 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
Background/Purpose: Early biologic use can improve long-term control of RA, and early use of abatacept (ABA) + MTX has demonstrated sustained improvements in selected patient-reported…Abstract Number: 1424 • 2019 ACR/ARP Annual Meeting
The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
Background/Purpose: Mechanistic differences between biologic DMARDs are poorly understood. Exploring these mechanisms includes assessing the role of HLA-DRB1 alleles containing the shared epitope (SE), which…Abstract Number: 1425 • 2019 ACR/ARP Annual Meeting
Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a marker for early, erosive RA.1 In the Abatacept (ABA) versus adaliMumab (ADA) comParison in bioLogic-naïvE RA subjects with…Abstract Number: 1426 • 2019 ACR/ARP Annual Meeting
Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. It was approved for RA by the US FDA in Nov 2012. TNFi…Abstract Number: 1427 • 2019 ACR/ARP Annual Meeting
Comparison of Real-World Persistence of Subcutaneously Administered Biologic Disease-Modifying Antirheumatic Drug Therapies Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Background/Purpose: The EULAR and ACR clinical guidelines recommend switching to a different disease-modifying antirheumatic drug (DMARD) when biologic-treated patients experience treatment failure or toxicity. Lack…Abstract Number: 1428 • 2019 ACR/ARP Annual Meeting
Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug which can be used as an alternative to biologic disease modifying antirheumatic drugs (bDMARDs) for rheumatoid…Abstract Number: 1429 • 2019 ACR/ARP Annual Meeting
Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis
Background/Purpose: Since January 2016, Chilean patients with rheumatoid arthritis (RA), with severe activity despite the use of 3 DMARDs for at least 6 months, have guaranteed access…Abstract Number: 1430 • 2019 ACR/ARP Annual Meeting
Predictors of Response to Etanercept-Methotrexate Treatment: Post-hoc Analysis of a Randomized, Open-label Study in Latin American Patients with Rheumatoid Arthritis
Background/Purpose: Etanercept (ETN) plus methotrexate (MTX) was shown to be superior to MTX plus another conventional disease-modifying anti-rheumatic drug (DMARD) in an open-label, randomized study…Abstract Number: 1431 • 2019 ACR/ARP Annual Meeting
Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study
Background/Purpose: The GO PRACTICE study was initiated following a demand by the French Health Authorities for long-term data on the real-life use of golimumab (GLM)…Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…Abstract Number: 1433 • 2019 ACR/ARP Annual Meeting
Association Between Seropositivity and Discontinuation of Tumor Necrosis Factor Inhibitors Due to Insufficient Response in Rheumatoid Arthritis
Background/Purpose: Discontinuation of biologic therapy in rheumatoid arthritis is attributable to various reasons, with the most important cause being insufficient response. In this study, we…
- « Previous Page
- 1
- …
- 851
- 852
- 853
- 854
- 855
- …
- 2425
- Next Page »